KCNH2

Voltage-gated inwardly rectifying potassium channel KCNH2 · Q12809 · KCNH2 on Sugi Atlas →

1,692,800 patent compounds predicted against KCNH2, 1,087,471 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Astemizole (SCHEMBL4385)	1.00	10/20
Mizolastine (SCHEMBL5061)	1.00	10/20
SCHEMBL2407	0.65	8/20
SCHEMBL1641	0.59	8/20
Amitriptyline (SCHEMBL7824)	1.00	7/20
Hydrochloric Acid (SCHEMBL1881)	0.65	7/20
Azelastine (SCHEMBL4239)	1.00	6/20
Azelastine (SCHEMBL4240)	1.00	6/20
Promethazine (SCHEMBL4700)	1.00	6/20
Carbinoxamine (SCHEMBL5070)	1.00	6/20
Hydrochloric Acid (SCHEMBL2524)	0.91	6/20
Erythromycin Propionate (SCHEMBL3331)	0.71	6/20
Erythromycin (SCHEMBL2601)	1.00	5/20
Erythromycin (SCHEMBL2602)	1.00	5/20
Dexchlorpheniramine (SCHEMBL3538)	1.00	5/20
Cyproheptadine (SCHEMBL4021)	1.00	5/20
Chlorpheniramine (SCHEMBL4219)	1.00	5/20
Chlorpheniramine (SCHEMBL4220)	1.00	5/20
Chlorcyclizine (SCHEMBL4383)	1.00	5/20
Chlorpromazine (SCHEMBL8321)	1.00	5/20

Clinical trials — most relevant to KCNH2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease	PHASE4	NOT_YET_RECRUITING
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)	PHASE4	UNKNOWN
Targeted Potassium Levels for Prevention of ICD Therapy	PHASE4	ACTIVE_NOT_RECRUITING
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation	PHASE3	COMPLETED
Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)	PHASE2/PHASE3	RECRUITING
Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients	PHASE3	NOT_YET_RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085	PHASE1	RECRUITING
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males	PHASE1	COMPLETED
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours	PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
Families' Experiences of Paediatric ICC Diagnosis	nan	UNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNH2 binder may also engage these)

Protein	Name	Similarity
Q9TUI4	—	1.000	Q9TUI4 →
Q8WNY2	—	1.000	Q8WNY2 →
O08703	—	1.000	O08703 →
Q9TSZ3	—	1.000	Q9TSZ3 →
O35219	—	1.000	O35219 →
O08962	—	1.000	O08962 →
O54853	—	0.999	O54853 →
Q9R1T9	—	0.998	Q9R1T9 →
O89047	—	0.994	O89047 →
KCNH3	Voltage-gated inwardly rectifying potassium channel KCNH3	0.994	landscape →
Q9PT84	—	0.993	Q9PT84 →
Q9WVJ0	—	0.993	Q9WVJ0 →
P97414	—	0.992	P97414 →
O54852	—	0.992	O54852 →
Q02280	—	0.991	Q02280 →
Q9NS40	—	0.991	Q9NS40 →
Q60603	—	0.991	Q60603 →
Q9ER47	—	0.990	Q9ER47 →
Q96L42	—	0.990	Q96L42 →
Q9TTJ7	—	0.989	Q9TTJ7 →
G5EFJ9	—	0.989	G5EFJ9 →
P0C550	—	0.989	P0C550 →
KCNQ5	Potassium voltage-gated channel subfamily KQT member 5	0.989	landscape →
Q9H252	—	0.988	Q9H252 →
Q9Z351	—	0.988	Q9Z351 →
CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	0.988	landscape →
P59111	—	0.988	P59111 →
O88944	—	0.988	O88944 →
O97531	—	0.988	O97531 →
P58126	—	0.988	P58126 →